期刊文献+

沙库必曲中间体的合成

Synthesis of Sacubitril Intermediates
下载PDF
导出
摘要 以D-苯丙氨酸为原料,经碘代、酯化、BOC保护、偶联、还原合成了沙库必曲的重要中间体——(R)-叔丁基(1-[(1,1′-联苯)-4-基]-3-羟基丙烷-2-基)氨基甲酸酯。反应总收率为46.17%。此工艺具有原料易得、收率较高、质量较好等优点。 An important intermediate of sacubitril-- (R)-tert-butyl-(1-([1,1 '-biphenyl]-4-yl)- 3-hydroxypropan-2-yl)carbamate synthesized by iodine generation, esterification, Boc protection, coupling and reduction from D-Phenylalanine. The overall yield of the reaction was 46.17 %. This method has several advantages of cheap reagents, high yield and good quality.
作者 俞风山 孙光祥 孙海江 周文 Yu Fengshan Sun Guangxiang Sun Haijiang Zhou Wen(Changzhou Pharmaceutical Factory Co., Ltd, Changzhou 213018, China)
出处 《广东化工》 CAS 2017年第20期88-88,55,共2页 Guangdong Chemical Industry
关键词 沙库必曲 合成 中间体 sacubitrih synthesis intermediate
  • 相关文献

参考文献3

二级参考文献23

  • 1姜红,葛均波.心力衰竭流行病学特点[J].中国医学前沿杂志(电子版),2010,2(1):1-5. 被引量:90
  • 2GASIOROWSKI A, DUTKIEWICZ J. Comprehen- sive rehabilitation in chronic heart failure [J]. Ann Agric Environ Med, 2013, 20: 606--612.
  • 3ZUCKER I H, XIAO L, HAACK K K V, et al. The central RAS and sympathetic nerve activity in chronic heart failure [J]. Clin Sci (Lond), 2014, 126:695-- 706.
  • 4MCMURRAY J J V. CONSENSUS to EMPHASIS; the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the corner- stone of therapy for systolic heart failure [J]. Eur J Heart Fail, 2011,13: 929--936.
  • 5VARDENY O, TACHENY T, SOLOMON S D. First-in-class angiotensin receptor neprilysin inhibitor in heart failure [J]. Clin Pharmacol Ther, 2013, 94: 445--448.
  • 6ORLY VARDENY P, MILLER R, SOLOMON S D. Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure [J]. JACC Heart Fail, 2014, 6: 663--670.
  • 7KOMUKAI K, YAGI H, OGAWA T, et al. Inhibi- tion of the renin-angiotensin system prevents re-hos- pitalization of heart failure patients with preserved e- jection fraction[J]. CircJ, 2008, 72: 2004-2008.
  • 8FERRAR10 C. Effect of angiotensin receptor block- ade on endothelial function: focus on olmesartan med- oxomil[J]. Vasc Health Risk Manag, 2009,5 : 301--314.
  • 9LI C, BOOZE R M, HERSH L B. Tissue-specific ex- pression of rat neutral endopeptidase (neprilysin) mRNAs [J]. J Biolog Chem, 1995, 270: 5723-- 5728.
  • 10STANDEVEN K F, HESS K, CARTER A M, et al. Neprilysin, obesity and the metabolic syndrome [J]. Intern J Obes, 2010, 35: 1031--1040.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部